Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title Sort descending | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional) | PAR-23-098 | NHGRI | 1.The Centers of Excellence in Genomic Science (CEGS) program establishes academic Centers for advanced genome research. Each CEGS award supports a multi-investigator, interdisciplinary team to… More | ||
| Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed) | RFA-DA-23-056 | NIDA | This Funding Opportunity Announcement (FOA) will support transformative research to identify and validate mechanisms, signaling pathways, and therapeutic targets, for understanding and reversing the… More | ||
| Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed) | RFA-DA-25-007 | NIDA | HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The… More | ||
| Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R21 Clinical Trial Not Allowed) | RFA-DA-25-008 | NIDA | HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The… More | ||
| Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed) | PAR-23-193 | NICHD | The NICHD has a state-of-the-art Chemical Synthesis and Optimization Facility for advancing both non-hormonal contraceptive and reproductive health related product development. This facility has the… More | ||
| Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional) | PAR-22-104 | FIC | This funding opportunity announcement (FOA) is a reissue due to an omission of TRAINING RECORD review questions in Section V. This FOA encourages applications for the Chronic, Non-Communicable… More | ||
| ClinGen Genomic Curation Expert Panels (U24 Clinical Trial Not Allowed) | PAR-23-199 | NICHD | NIH established a clinical genomics infrastructure to develop an openly accessible knowledgebase that promotes data sharing and provides standardized infrastructure and tools for determining the… More | ||
| Clinical and Translational Science Award (UM1 Clinical Trial Optional) | PAR-21-293 | NCATS | This funding opportunity announcement (FOA) invites applications for the Clinical and Translational Science Award (CTSA) Program hubs that will be part of a national, collaborative consortium focused… More | ||
| Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | PAR-21-329 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic… More | ||
| Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) | PAR-22-192 | NHLBI | This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including… More |